Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1993-5-27
|
pubmed:abstractText |
Oxitropium bromide is a quaternary anticholinergic compound based on the scopolamine molecule instead of atropine. The purpose of this study was to compare the bronchodilator effects of oxitropium, a beta 2-agonist fenoterol, and their combination, on basal bronchomotor tone in normal subjects. Partial flow-volume curve (PEF25), was measured as an index representing bronchomotor tone. The cumulative dose-response curve of oxitropium bromide inhaled from a metered-dose inhaler was determined in eleven normal subjects. Measurement of PEF25 was repeated every 1 h for 8 h after inhalation of oxitropium (200 micrograms), fenoterol (200 micrograms), their combination or placebo in six normal subjects in a randomized, single-blinded, placebo-controlled, cross-over manner. As the percentage increase in PEF25 by 200 micrograms of oxitropium (45 +/- 6%) was equivalent to nearly 80% of that by dose of 1,600 micrograms (58 +/- 8%), the dose of 200 micrograms is thought to be appropriate. The group mean percentage increase in the PEF25-time course curve was significantly greater after treatment with the combination than with placebo (p < 0.001) and fenoterol (p < 0.001) but not with oxitropium bromide, while the increase in PEF25 following the combination was significantly greater than that following oxitropium bromide after 2 and 3 h. These findings indicate that in normal subjects oxitropium has a powerful bronchodilator effect and that the addition of oxitropium to fenoterol caused greater bronchodilation in normal subjects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fenoterol,
http://linkedlifedata.com/resource/pubmed/chemical/Parasympatholytics,
http://linkedlifedata.com/resource/pubmed/chemical/Scopolamine Derivatives,
http://linkedlifedata.com/resource/pubmed/chemical/oxitropium
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0959-9851
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
31-5
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8477178-Adult,
pubmed-meshheading:8477178-Bronchodilator Agents,
pubmed-meshheading:8477178-Dose-Response Relationship, Drug,
pubmed-meshheading:8477178-Drug Combinations,
pubmed-meshheading:8477178-Female,
pubmed-meshheading:8477178-Fenoterol,
pubmed-meshheading:8477178-Forced Expiratory Volume,
pubmed-meshheading:8477178-Humans,
pubmed-meshheading:8477178-Parasympatholytics,
pubmed-meshheading:8477178-Scopolamine Derivatives,
pubmed-meshheading:8477178-Single-Blind Method,
pubmed-meshheading:8477178-Vital Capacity
|
pubmed:year |
1993
|
pubmed:articleTitle |
Bronchodilator effects of oxitropium bromide, fenoterol, and their combination in normal subjects.
|
pubmed:affiliation |
Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|